Anticipe

What Anticipe does

Anticipe (UMRS 1086) is a multidisciplinary research unit affiliated with Université de Caen Normandie and co-located at the Centre François Baclesse cancer center in Caen, France. The unit develops research approaches to address public health challenges principally in oncology, spanning four domains articulated on its institutional homepage: prevention, screening, therapeutic innovation, and patient accompaniment (accompagnement des patients). Its work is organized into five interconnected research programs: (1) occupational and environmental cancer risk factors, (2) living with cancer (quality of life, supportive and palliative care), (3) health, inequalities, territory and environment, (4) healthcare pathways and transitional phases, and (5) precision medicine for ovarian cancer. The unit has 23 staff, a French-only operating geography confined to Normandy, and an institutional website at anticipe.unicaen.fr supplemented by a LinkedIn corporate page (Anticipeu1086).

The unit's underlying 'technology' is academic methodology rather than commercial technology: multidisciplinary research approaches combining epidemiology, clinical research, and health services research across its five program areas. There are no disclosed proprietary software products, APIs, SDKs, patents, or trademarks in the input data. Research outputs are disseminated through a dedicated 'Productions scientifiques' (scientific productions) publication track and through formation (training) activities delivered under the university framework. No AI/ML, data platform, or commercial software capabilities are evidenced.

Anticipe is not a commercial entity. The input explicitly states that pricing is not applicable because Anticipe is a university research unit, and the unit is privately classified in type but operationally a publicly funded academic body. It operates under the governance of Université de Caen Normandie and is hosted at Centre François Baclesse (3 avenue du général Harris, BP 5026, 14076 Caen Cedex 5). No venture capital, private equity, independent ownership, subsidiaries, funding rounds, acquisitions, or commercial distribution channels are indicated. The unit's counterparties are the French academic and public research system rather than enterprise customers.

Name

Anticipe

Website

https://anticipe.eu

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Anticipe (UMRS 1086) is an academic research unit at Université de Caen Normandie and Centre François Baclesse in France, conducting multidisciplinary public health research in oncology across prevention, screening, therapeutic innovation, and patient support.

Ownership category

akta.pro rank

Product category

Public Health Cancer Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Gynecologic Oncology (HLAKAFAF), Non-Communicable Disease Prevention & Chronic Disease Programs (BPAIAJAI)

Keywords

• Cancer research
• Public health research
• Oncology epidemiology
• Precision medicine
• Healthcare pathways

Headquarters

HQ city

Caen

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Marketing channels1 record

Core offering

Anticipe is a university research unit (UMRS 1086) affiliated with Université de Caen Normandie and hosted at Centre François Baclesse in Caen, France. It conducts multidisciplinary public health research in oncology across five programs: occupational and environmental cancer risk factors, living with cancer, health inequalities-territory-environment, healthcare pathways and transitions, and precision medicine for ovarian cancer. Deliverables include scientific publications, academic training, and registries rather than commercial products.

Product overview

Anticipe (UMRS 1086) is a multidisciplinary research unit affiliated with Université de Caen Normandie and Centre François Baclesse. Rather than a technology product company, Anticipe develops five interconnected research programs focused on public health issues primarily in oncology: occupational and environmental cancer risk factors, living with cancer, health inequalities and environment, healthcare pathways and transitions, and precision medicine for ovarian cancer. These research areas span prevention, screening, therapeutic innovation, and patient support.

Differentiator

Problem solved

Functional benefit

Products and services

• Occupational and Environmental Cancer Risk Factors Research Program (Facteurs de risques professionnels et environnementaux des cancers) Research program investigating how occupational and environmental exposures contribute to cancer development, targeting public-health researchers, epidemiologists, and policy stakeholders working on cancer prevention.
• Living with Cancer Research Program (Vivre avec un cancer) Research program focused on quality of life, supportive care, and palliative care throughout the cancer patient journey, serving oncology researchers, clinicians, and patient-support stakeholders.
• Health, Inequalities, Territory, Environment Research Program (Santé, Inégalités, Territoire, Environnement) Research program examining health inequalities, territorial disparities, and environmental factors affecting population health outcomes, serving public-health researchers, regional health agencies, and policy stakeholders.
• Healthcare Pathways and Transition Phases Research Program (Parcours de santé et phases de transition) Research program studying healthcare pathways and care-transition phases, including care coordination across providers, targeting health-services researchers, clinicians, and health-system stakeholders.
• Precision Medicine for Ovarian Cancer Research Program (Médecine de précision des cancers de l'ovaire) Research program on precision medicine for ovarian cancer, including personalized therapeutic strategies and targeted therapies, serving translational oncology researchers and clinical specialists.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Université de Caen NormandiecoreStrategic or Co-development PartnerAnticipe is an integral research unit (UMRS 1086) affiliated with Université de Caen Normandie, operating within the university's academic and research framework to conduct multidisciplinary public health research primarily in oncology.

Recent moves1 record

Expansion highlights3 records

Broad incumbents

• Institut Paoli-Calmettes: Marseille-based French Comprehensive Cancer Center affiliated with Aix-Marseille Université and INSERM. Comparable to Anticipe as a regional oncology research and care institution with strong public-health and translational research programs in the French academic system.
• International Agency for Research on Cancer (IARC): WHO specialized agency headquartered in Lyon, France, conducting and coordinating international research on cancer etiology and prevention. Comparable to Anticipe's occupational/environmental risk factor and health-inequalities research programs, though at a global rather than regional scale.
• UNICANCER: Federation of the 18 French Comprehensive Cancer Centers (CLCCs) including Centre François Baclesse (Anticipe's host institution). Comparable as the umbrella coordinating body for oncology research, clinical trials, and public-health programs across the French cancer center network.
• Gustave Roussy: Premier European cancer center and research institute located in Villejuif, France. Comparable to Anticipe in its multidisciplinary oncology research scope and academic affiliation, though operating at significantly greater scale and with a global patient catchment.
• Centre Léon Bérard: French Comprehensive Cancer Center (CLCC) in Lyon affiliated with Université Claude Bernard and INSERM. Comparable as a hospital-integrated oncology research unit with university ties and multidisciplinary cancer research programs similar in structure to Anticipe's.
• Institut Curie: Leading French cancer research and treatment center combining a hospital, a research center, and a technology transfer arm. Comparable to Anticipe in its blend of basic, translational, and clinical oncology research, but far larger and with a much broader national footprint.
• European Organisation for Research and Treatment of Cancer (EORTC): International non-profit based in Brussels conducting multidisciplinary cancer clinical and translational research across Europe. Comparable to Anticipe's care-pathway, precision-medicine, and quality-of-life research themes, but operating as a pan-European network rather than a single regional unit.

Direct peers

• Karolinska Institutet - Department of Oncology-Pathology: Swedish university-based oncology research department conducting multidisciplinary cancer research from prevention and epidemiology through to precision therapeutics. Comparable to Anticipe as a university-embedded research unit with multiple thematic oncology programs.

Others

• CNRS - Centre National de la Recherche Scientifique: France's largest public research organization. Comparable as the parent ecosystem within which many French academic research units (similar in governance to Anticipe) operate, providing infrastructure, evaluation, and co-funding that shape the research environment in which Anticipe competes.
• INSERM U1086 - Anticipe (historical record): INSERM is Anticipe's co-tutelle supervisory institution. Listed as an 'others' peer because it provides the structural template (mixed research units, INSERM/University joint governance) within which Anticipe operates and against which peer INSERM oncology units (e.g., UMR-S 1193, UMR-S 1138) compete for funding.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/anticipeu1086

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anticipe